NEWS & INSIGHTS /

Cure51's CEO Nicolas Wolikow: How does AI help advance our Rosalind Study?

Rosalind Study

Inside Cure51

The science

Publication Date:
TO READ NEXT

Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

How does AI help advance our Rosalind Study? Our CEO Nicolas Wolikow breaks it down in an interview with FW.MEDIA.

Credit: FW.MEDIA

Nicolas Wolikow, CEO


Updated: April 1, 2026

Table of Contents
in THIS ARTICLE
In this article

NICOLAS WOLIKOW

Co-Founder CEO

MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES
sfp-cure51-pancreatic-cancer copy

Cure51 at the SFP Congress: What Exceptional Pancreatic Cancer Survival Can Teach Us About Pancreatic Cancer

sfp-cure51-pancreatic-cancer copy

Cure51 at the SFP Congress: What Exceptional Pancreatic Cancer Survival Can Teach Us About Pancreatic Cancer

Nicolas-Wolikow-Cure51-Servier-Partnership-Glioblastoma

Our CEO Nicolas Wolikow: "Our New Partnership with Servier Reflects Our Unique Approach to Glioblastoma Research"

Nicolas-Wolikow-Cure51-Servier-Partnership-Glioblastoma

Our CEO Nicolas Wolikow: "Our New Partnership with Servier Reflects Our Unique Approach to Glioblastoma Research"

Ashley-Lakner-cure51-servier

Ashley Lakner, CSO: “The partnership with Servier opens new opportunities to identify therapeutic targets for glioblastoma”

Ashley-Lakner-cure51-servier

Ashley Lakner, CSO: “The partnership with Servier opens new opportunities to identify therapeutic targets for glioblastoma”

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

READ MORE

TOP STORIES

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

precision-medicine-nicolas-wolikow

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

Building a Product Ecosystem for Cancer Target Discovery

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

CHUV Lausanne received their Rosalind trophy!

CHUV-Centre-hospitalier-universitaire-vaudois

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

precision-medicine-nicolas-wolikow

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Global-Cancer-Research-Compliance

NEWS & INSIGHTS

TOP STORIES

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

Contact us

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

Follow us

Linkedin

Facebook

Instagram

Contact us

Contact us

Follow us

Linkedin

Facebook

Instagram

Contact us

ROSALIND

Contact us